This study is researching the option of using alternate sites of administration, like infusion centers, to receive CABENUVA injections. CABENUVA is an FDA-approved HIV treatment given as two injections once every month or once every 2 months. The GLACIER study is researching the option of using alternate sites of administration, such as infusion centers, for giving these injections. What we learn
in this study will help us make sure people who are prescribed CABENUVA can receive their injections in a way that works for them and their healthcare provider. With the help of volunteer study participants, we want to answer the following questions:
• How easy or hard is it for you to use an alternate site of administration, such as an infusion center? (feasibility)
• What do you like or not like about using an alternate site of administration? (acceptability)
• What could be done to increase the feasibility and acceptability of using an alternate site of administration? Why use alternate site of administration for CABENUVA treatment? What are infusion centers? The use of alternative sites of administration, like infusion centers, may help ensure people who are prescribed CABENUVA can receive their injections in a way that works for them and their healthcare provider. Alternate sites of administration, such as infusion centers, are medical facilities that:
• Routinely administer injectable treatments to a diverse patient population
• Have trained medical staff onsite
• Can communicate directly with your healthcare providers
• Are not diagnosis specific, which allows for an added level of privacy
• May provide increased flexibility in scheduling CABENUVA injections
Who can take part in the GLACIER study? You may be able to take part in this study if you:
• Are at least 18 years old and living with diagnosed HIV-1 infection
• Have been prescribed CABENUVA
• Agree to receive CABENUVA injections at a participating alternate site of administration for 8 months
You will also need to meet additional requirements. The study team will review these with you. What will you need to do in the GLACIER study? In addition to receiving CABENUVA injections at an alternate site of administration, you will:
• Complete questionnaires about receiving injections at the alternate site of administration
• Continue to see your usual healthcare providers for all other aspects of your healthcare
• Have blood samples taken at some visits for safety tests and other assessments
You may also be selected for a phone interview in the last month of the study. Do you have to stay in the study? You can leave the study at any time. Your choice will not change the quality of care you receive outside of this study. It will also not affect your ability to receive CABENUVA now or in the future. You can choose to continue to receive CABENUVA injections at the alternate site of administration even if you leave the study. How do you join the GLACIER study? You should talk with your healthcare provider about this study. Together you can decide if taking part in the study could be right for you. To learn more about the GLACIER study visit: https://glacierhivstudy.com
